Review: Cancer-induced autoimmunity in the rheumatic diseases

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 317-326

  Shah, Ami A ^a   Casciola Rosen, Livia ^a   Rosen, Antony ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 2; RNA POLYMERASE III ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; AUTOIMMUNITY; BREAST CANCER; CANCER RISK; DIABETES MELLITUS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; MYOSITIS; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SCLERODERMA; AUTOIMMUNE DISEASE; DERMATOMYOSITIS; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; PATHOPHYSIOLOGY; SYSTEMIC SCLEROSIS;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC;

EID: 84922822961     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38928     Document Type: Review

References (74)

1. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
2. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 742-64.
3. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343: 152-7.
4. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L,. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-95.
5. Abu-Shakra M, Guillemin F, Lee P,. Cancer in systemic sclerosis. Arthritis Rheum 1993; 36: 460-4.
6. Derk CT, Rasheed M, Artlett CM, Jimenez SA,. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33: 1113-6.
7. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P,. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62: 728-31.
8. Olesen AB, Svaerke C, Farkas DK, Sorensen HT,. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Rheumatol 2010; 163: 800-6.
9. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O,. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 910-4.
10. Rosenthal AK, McLaughlin JK, Linet MS, Persson I,. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993; 52: 531-3.
11. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM,. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985; 12: 1136-9.
12. Siau K, Laversuch CJ, Creamer P, O'Rourke KP,. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 2011; 31: 641-5.
13. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2013; 52: 143-54.
14. Onishi A, Sugiyama D, Kumagai S, Morinobu A,. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013; 65: 1913-21.
15. Zhang JQ, Wan YN, Peng WJ, Yan JW, Li BZ, Mei B, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol 2013; 37: 523-7.
16. Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012; 41: 44-9.
17. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT,. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12: R70.
18. Airio A, Pukkala E, Isomaki H,. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22: 1300-3.
19. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G,. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
20. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr., Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6: 9-13.
21. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
22. Stockton D, Doherty VR, Brewster DH,. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85: 41-5.
23. Zahr ZA, Baer AN,. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-15.
24. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
25. Derk CT,. Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol 2007; 26: 1615-9.
26. Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-7.
27. Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64-71.
28. Zantos D, Zhang Y, Felson D,. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21: 1855-9.
29. Colaci M, Giuggioli D, Vacchi C, Lumetti F, Iachetta F, Marcheselli L, et al. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 2014; 13: 132-7.
30. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
31. Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35: 438-44.
32. Hasegawa M, Sato S, Sakai H, Ohashi T, Takehara K,. Systemic sclerosis revealing T-cell lymphoma. Dermatology 1999; 198: 75-8.
33. Juarez M, Marshall R, Denton C, Evely R,. Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology (Oxford) 2008; 47: 1734-5.
34. Mammen AL,. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
35. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 74-34.
36. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL,. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-66.
37. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-21.
38. Mimura Y, Takahashi K, Kawata K, Akazawa T, Inoue N,. Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci 2010; 123: 2014-24.
39. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 74-8.
40. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.
41. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW,. Autoantibodies to transcriptional intermediary factor 1-γ(TIF1-γ) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54 Suppl: S518.
42. Massague J, Xi Q,. TGF-β control of stem cell differentiation genes. FEBS Lett 2012; 586: 1953-8.
43. Xi Q, Wang Z, Zaromytidou AI, Zhang XH, Chow-Tsang LF, Liu JX, et al. A poised chromatin platform for TGF-β access to master regulators. Cell 2011; 147: 1511-24.
44. Hesling C, Lopez J, Fattet L, Gonzalo P, Treilleux I, Blanchard D, et al. Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development 2013; 140: 167-75.
45. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-32.
46. Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco JA, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997; 40 Suppl: S139.
47. Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV,. Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum 2007; 56 Suppl: S787.
48. Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem 2002; 277: 20611-7.
49. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al, for the Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807-14.
50. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV,. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 7447-51.
51. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
52. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710-3.
53. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954-62.
54. Harris ML, Rosen A,. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003; 15: 778-84.
55. Steen VD,. The many faces of scleroderma. Rheum Dis Clin North Am 2008; 34: 1-15, v.
56. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
57. Shah AA, Wigley FM,. My approach to the treatment of scleroderma. Mayo Clin Proc 2013; 88: 377-93.
58. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F,. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38: 1329-34.
59. Shah AA, Rosen A,. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011; 23: 530-5.
60. Lin RH, Mamula MJ, Hardin JA, Janeway CA Jr., Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med 1991; 173: 1433-9.
61. Mamula MJ, Lin RH, Janeway CA Jr, Hardin JA,. Breaking T cell tolerance with foreign and self co-immunogens: a study of autoimmune B and T cell epitopes of cytochrome c. J Immunol 1992; 149: 789-95.
62. Darnell RB, Posner JB,. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-54.
63. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
64. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-80.
65. Albert ML, Darnell RB,. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004; 4: 36-44.
66. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
67. Burnet M,. Cancer: a biological approach. I. The processes of control. Br Med J 1957; 1: 779-86.
68. Stutman O,. Immunodepression and malignancy. Adv Cancer Res 1975; 22: 261-422.
69. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD,. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
70. Poduri A, Evrony GD, Cai X, Walsh CA,. Somatic mutation, genomic variation, and neurological disease. Science 2013; 341: 1237758.
71. Matzinger P,. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
72. Sigurgeirsson B, Lindelof B, Edhag O, Allander E,. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med 1992; 326: 363-7.
73. Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Rheumatol 2009; 161: 854-60.
74. Chatterjee S, Dombi GW, Severson RK, Mayes MD,. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52: 2415-24.